Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12436727 | 0.82 | SIGMAR1 (0.58) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL25823578 | 0.79 | TMEM97 (0.44) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL20570318 | 0.76 | PNMT (0.42) | TMEM97SIGMAR1PNMTTAAR1MEN1 | |
| SCHEMBL8294365 | 0.75 | MAPT (0.49) | MEN1KMT2A | |
| SCHEMBL20974679 | 0.75 | PNMT (0.43) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL12767968 | 0.75 | THRA (0.33) | THRATHRB | |
| SCHEMBL15921609 | 0.75 | KDM4E (0.47) | SIGMAR1PNMTTAAR1ABL1 | |
| SCHEMBL3238220 | 0.75 | TAAR1 (0.67) | SIGMAR1PNMTTAAR1 | |
| SCHEMBL18996666 | 0.74 | TMEM97 (0.43) | TMEM97SIGMAR1KCNH2PNMTTAAR1 | |
| SCHEMBL12188730 | 0.74 | ABL1 (0.43) | SIGMAR1PNMTTAAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | TMEM97 3475/4885SIGMAR1 1833/4885KCNH2 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.